CAS Registry Services℠
Challenges and opportunities
Leading data, scientific, and pharmaceutical experts discuss the current challenges in drug discovery and potential opportunities to improve the process.
Can AI assist synthetic biology for new drug development?
Nathan Lanclos and Graham Hudson, Ph.D., and from the University of California, Berkeley, Keasling Lab and the Joint BioEnergy Institute (JBEI)
How do predictive models empower drug discovery?
Adam Sanford, Ph.D., and Orr Ravitz, Ph.D., from CAS
How can prioritizing data accelerate drug discovery?
Zoheb Hassan, Ph.D., from Frost & Sullivan
Can we expand therapies by reaching for undruggable targets?
Mauro Mileni, Ph.D., and Chris Roth, Ph.D., from Abilita Therapeutics
Why are new authority constructs necessary for life sciences data?
Nicole Stobart, Jeff Wilson, Ph.D., and Mark Schmidt from CAS
How well do models predict protein functions?
Iddo Friedberg, Ph.D., from Iowa State University
Do you need a computational biologist for sequence analysis?
Jefferson Parker, Ph.D., from NullSet Informatics Solutions
What’s the benefit of AI/ML for structure-activity relationship studies?
Ben R. Taft, Ph.D., from Via Nova Therapeutics
Learn more about how CAS can help you with your drug discovery efforts.
